These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 36430675)
1. Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer. Gianni C; Palleschi M; Merloni F; Di Menna G; Sirico M; Sarti S; Virga A; Ulivi P; Cecconetto L; Mariotti M; De Giorgi U Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430675 [TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy in breast cancer: A comprehensive review. Alimirzaie S; Bagherzadeh M; Akbari MR Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931 [TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients. Zavarykina TM; Lomskova PK; Pronina IV; Khokhlova SV; Stenina MB; Sukhikh GT Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069396 [TBL] [Abstract][Full Text] [Related]
4. Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer. Fernandez-Garcia D; Hills A; Page K; Hastings RK; Toghill B; Goddard KS; Ion C; Ogle O; Boydell AR; Gleason K; Rutherford M; Lim A; Guttery DS; Coombes RC; Shaw JA Breast Cancer Res; 2019 Dec; 21(1):149. PubMed ID: 31856868 [TBL] [Abstract][Full Text] [Related]
5. Blood has never been thicker: Cell-free DNA fragmentomics in the liquid biopsy toolbox of B-cell lymphomas. Meriranta L; Pitkänen E; Leppä S Semin Hematol; 2023 Jul; 60(3):132-141. PubMed ID: 37455222 [TBL] [Abstract][Full Text] [Related]
6. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival. Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review. Cervena K; Vodicka P; Vymetalkova V Mutat Res Rev Mutat Res; 2019; 781():100-129. PubMed ID: 31416571 [TBL] [Abstract][Full Text] [Related]
8. Measuring cfDNA integrity as a biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients: a pilot study. Giro C; Yamada AMTD; Cruz FJSM; do R Barros LA; da C A Alves B; Fonseca FLA; Del Giglio A Breast Cancer Res Treat; 2024 Jul; 206(2):329-335. PubMed ID: 38743176 [TBL] [Abstract][Full Text] [Related]
9. Clinical utility of liquid biopsy in breast cancer: A systematic review. Duque G; Manterola C; Otzen T; Arias C; Galindo B; Mora M; Guerrero E; García N Clin Genet; 2022 Mar; 101(3):285-295. PubMed ID: 34687555 [TBL] [Abstract][Full Text] [Related]
10. Cell-free DNA concentration in patients with clinical or mammographic suspicion of breast cancer. Peled M; Agassi R; Czeiger D; Ariad S; Riff R; Rosenthal M; Lazarev I; Novack V; Yarza S; Mizrakli Y; Douvdevani A Sci Rep; 2020 Sep; 10(1):14601. PubMed ID: 32884019 [TBL] [Abstract][Full Text] [Related]
11. The applications of plasma cell-free DNA in cancer detection: Implications in the management of breast cancer patients. Igari F; Tanaka H; Giuliano AE Crit Rev Oncol Hematol; 2022 Jul; 175():103725. PubMed ID: 35618229 [TBL] [Abstract][Full Text] [Related]
12. A Case-Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection. Bortul M; Giudici F; Tierno D; Generali D; Scomersi S; Grassi G; Bottin C; Cappelletti MR; Zanconati F; Scaggiante B Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239866 [TBL] [Abstract][Full Text] [Related]
13. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Luo H; Wei W; Ye Z; Zheng J; Xu RH Trends Mol Med; 2021 May; 27(5):482-500. PubMed ID: 33500194 [TBL] [Abstract][Full Text] [Related]
14. Liquid biopsy prediction of axillary lymph node metastasis, cancer recurrence, and patient survival in breast cancer: A meta-analysis. Lee JH; Jeong H; Choi JW; Oh HE; Kim YS Medicine (Baltimore); 2018 Oct; 97(42):e12862. PubMed ID: 30334995 [TBL] [Abstract][Full Text] [Related]
15. Liquid biopsy and its role in an advanced clinical trial for lung cancer. Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770 [TBL] [Abstract][Full Text] [Related]
16. Evaluating circulating cell-free DNA and DNA integrity index as biomarkers in non-small cell lung cancer. Ezzeldin N; El-Lebedy D; Hassan M; Shalaby AO; Hussein SAM; Gharib AM; Hamdy G; Mohammed AM; Ramadan A; Sobeih ME J Egypt Natl Canc Inst; 2024 Jun; 36(1):21. PubMed ID: 38880832 [TBL] [Abstract][Full Text] [Related]
17. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. García-Pardo M; Makarem M; Li JJN; Kelly D; Leighl NB Br J Cancer; 2022 Sep; 127(4):592-602. PubMed ID: 35347327 [TBL] [Abstract][Full Text] [Related]
18. Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer. Zhang X; Ju S; Wang X; Cong H Clin Exp Med; 2019 Aug; 19(3):271-279. PubMed ID: 31190187 [TBL] [Abstract][Full Text] [Related]
19. Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast Cancer. Hussein NA; Mohamed SN; Ahmed MA Appl Biochem Biotechnol; 2019 Mar; 187(3):1028-1045. PubMed ID: 30151636 [TBL] [Abstract][Full Text] [Related]
20. Exploring the Role of Circulating Cell-Free RNA in the Development of Colorectal Cancer. Kan CM; Pei XM; Yeung MHY; Jin N; Ng SSM; Tsang HF; Cho WCS; Yim AK; Yu AC; Wong SCC Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446204 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]